A biotechnology company developing in vivo gene editing therapies designed to treat cardiovascular disease by permanently modifying genes in the liver. Its lead programs use base‑editing technology to target genes such as PCSK9 and ANGPTL3 with the goal of providing one‑time treatments for patients ...
No congressional trades have been disclosed for Verve Inc (VERV) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.